Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

Sigma-Aldrich Okays Licensing Agreement with Epigentek Group

  • Sigma-Aldrich signed a licensing agreement with Epigentek Group to further develop and commercialize technologies for epigenetics research.

    “Sigma-Aldrich has identified epigenetics as a growing area of interest and research for heritable diseases such as cancer, Alzheimer's, and many others,” says  Keith Jolliff, director of genomics and functional genomics at Sigma-Aldrich.

    Sigma-Aldrich thus gains rights to Epigentek technologies, including DNA modification, methylation quantitation, and protein/DNA interaction. This agreement is exclusive in the U.S. and co-exclusive globally.

    The company reports that it plans to launch a family of products for epigenetic research, beginning with the Imprint DNA Modification Kit later this month. It aims to provide a complete epigenetic solution from DNA purification and bisulfite conversion to detection, adds Jolliff.

    Other products launching under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek’s technologies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »